[Skip to Content]
Access to paid content on this site is currently suspended due to excessive activity being detected from your IP address 54.158.98.119. Please contact the publisher to request reinstatement.
[Skip to Content Landing]
Editorial
September 2015

Potential Synergy of Radiation Therapy With Vismodegib for Basal Cell Carcinoma

Author Affiliations
  • 1Departments of Surgery, Internal Medicine, and Biochemistry, Florida Atlantic University, Boca Raton, Florida
  • 2Lynn Cancer Institute, Moffitt Oncology Network, Boca Raton Regional Hospital, Boca Raton, Florida
JAMA Dermatol. 2015;151(9):925-926. doi:10.1001/jamadermatol.2015.0977

Basal cell carcinoma (BCC), when untreated, causes significant morbidity and mortality. Challenging tumors are regularly reviewed in multimodality tumor boards and are classified not by metastatic risk (inherently very low) but by histologic type and other tumor characteristics. Tumors are thus triaged appropriately to destruction, excision, topical therapy, Mohs surgery, or ionizing radiation therapies. The cure rate for BCC with monotherapy has largely exceeded that for other human cancers, prompting some to lose sight of the tremendous challenge it still creates.1 The increasing number of these cancers and the increasing longevity of patients leaves us with more complex BCC tumors to manage. We now have a type of chemotherapy available for BCC, and with the 2 cases reported in this issue of JAMA Dermatology, Pollom et al2 demonstrate the possibility of true combination therapy.

First Page Preview View Large
First page PDF preview
First page PDF preview
×